Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.265434 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Romain-David Seban und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
TO THE EDITOR: We have read with great interest the results of the DESTINY-Breast04 trial, “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,” from Modi et al. and published in The New England Journal of Medicine ([1][1]). These impressive findings have also earned a
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Seban, R. D., Champion, L., Bellesoeur, A., Vincent-Salomon, A., & Bidard, F. C. (2023). Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265434
Vancouver
Seban RD, Champion L, Bellesoeur A, Vincent-Salomon A, Bidard FC. Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265434
BibTeX
@article{Seban2023,
author = {Seban, Romain-David and Champion, Laurence and Bellesoeur, Audrey and Vincent-Salomon, Anne and Bidard, Francois-Clement},
title = {Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.265434}
}
EUVIMED